Faith L. Charles Buys 7,550 Shares of Abeona Therapeutics Inc (NASDAQ:ABEO) Stock

Abeona Therapeutics Inc (NASDAQ:ABEO - Get Free Report) Director Faith L. Charles bought 7,550 shares of the firm's stock in a transaction dated Friday, April 26th. The stock was bought at an average cost of $3.28 per share, with a total value of $24,764.00. Following the transaction, the director now directly owns 78,323 shares of the company's stock, valued at $256,899.44. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Abeona Therapeutics Trading Up 5.5 %

NASDAQ ABEO traded up $0.18 on Monday, hitting $3.44. 2,089,123 shares of the stock traded hands, compared to its average volume of 461,898. The stock has a 50-day moving average of $7.23 and a 200 day moving average of $5.62. The company has a market capitalization of $94.10 million, a P/E ratio of -1.33 and a beta of 1.49. Abeona Therapeutics Inc has a twelve month low of $2.83 and a twelve month high of $9.01.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its earnings results on Monday, March 18th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.13). As a group, equities research analysts expect that Abeona Therapeutics Inc will post -2.05 earnings per share for the current year.

Analyst Upgrades and Downgrades

ABEO has been the subject of a number of analyst reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $36.00 price target on shares of Abeona Therapeutics in a report on Tuesday, April 23rd. StockNews.com downgraded Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Tuesday, April 23rd.

Hedge Funds Weigh In On Abeona Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ABEO. Adage Capital Partners GP L.L.C. boosted its stake in Abeona Therapeutics by 84.5% during the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 3,249,994 shares of the biopharmaceutical company's stock valued at $13,682,000 after purchasing an additional 1,488,834 shares in the last quarter. AIGH Capital Management LLC boosted its stake in Abeona Therapeutics by 77.7% during the 3rd quarter. AIGH Capital Management LLC now owns 1,135,252 shares of the biopharmaceutical company's stock valued at $4,779,000 after purchasing an additional 496,278 shares in the last quarter. Citigroup Inc. boosted its stake in Abeona Therapeutics by 125.0% during the 3rd quarter. Citigroup Inc. now owns 450,000 shares of the biopharmaceutical company's stock valued at $1,894,000 after purchasing an additional 250,000 shares in the last quarter. Barclays PLC boosted its stake in Abeona Therapeutics by 100.0% during the 3rd quarter. Barclays PLC now owns 371,276 shares of the biopharmaceutical company's stock valued at $1,564,000 after purchasing an additional 185,638 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new position in Abeona Therapeutics during the 3rd quarter valued at $648,000. 80.56% of the stock is owned by institutional investors.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.